Market accessOfficial

Danish regulator updates supply notice for Rimactan 300 mg rifampicin capsules from 2care4

🇩🇰 DKMA · Tue 27 Oct 2026

DKMA's notice on Rimactan 300 mg hard capsules, first posted in March, was updated on 27 October 2026; supply problems began in mid-February with no end date.

The Danish Medicines Agency (DKMA) has updated its supply notice for Rimactan 300 mg hard capsules, a rifampicin product marketed by 2care4 ApS. The notice was first published on 5 March 2026 and revised on 27 October 2026.

DKMA describes the problems as current. The product's active substance is rifampicin, and its ATC code is J04AB02. The agency gives the expected period of disruption as mid-February 2026 to an unknown end date, so no resumption of normal supply is indicated.

The stated cause is delivery difficulties. The notice gives no further detail on the nature of those difficulties, the volumes affected or any alternative products. DKMA says questions about the current status should be put to the company, 2care4 ApS.

The notice sits within DKMA's published announcements on medicine supply. The agency also maintains separate pages on foreign alternatives when supply fails, but the source text for this item does not say whether any such alternative applies to Rimactan.

What it means for your team

  • Supply-chain and pharmacy teams in Denmark should treat Rimactan 300 mg capsules as unavailable or constrained, since the end date is listed as unknown.
  • For current stock status and expected resupply, contact 2care4 ApS directly, as DKMA advises.
  • Regulatory and market-access staff should monitor the DKMA notice for further updates, as it has already been revised once since March.
  • The notice does not mention mitigation measures, so check DKMA's pages on foreign alternatives for options.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Market access All →